Trading FDA, Clinical Trial Binary Events: $ACHN $JAZZ $BMY

Below are some Regulatory Catalyst Index updates for companies with recent FDA and clinical trial related news…

Achillion Pharma (NASDAQ:ACHN) expects to receive net proceeds of approximately $50 million from a private placement that includes the sale of common stock / warrants. ACHN plans to use the proceeds to fund Phase 2 clinical trials for its lead anti-viral hepatitis C virus (HCV) drug candidate ACH-1625 (HCV protease inhibitor) that are expected to begin this quarter in addition to planned Investigational New Drug (IND) applications early next year for a pair of additional HCV anti-viral drug candidates (ACH-2684, ACH-2928) for FDA clearance to begin Phase I clinical trials.

Below are summaries of the most recent articles written by Mark Messier at www.BioRunUp.com — please visit his website to read the full articles, in addition to many other free tools and strategies related to binary event investing and trading…

The Day of Reckoning for Jazz Pharma (NASDAQ:JAZZ)

The day of the FDA Advisory Panel is now upon us.  The notes have been released (link), trading has been halted, and all bets are on the table.  Now we get to sit back and enjoy following along with the FDA panel. What can you expect?  Basically a board meeting with a deciding vote at the [...]

FDA Calendar Updates 8/20/10

Human Genome Sciences (NASDAQ:HGSI) – 12/9/10 Priority PDUFA date for BENLYSTA

Bristol-Myers (NYSE:BMY) – 12/25/10 Priority Review for Ipilimumab

www.mikehavRx.com is your prescription for stock index investing updates focused on the healthcare sector, medical innovation, and binary event tracking for FDA decisions and clinical trials, including 600+ events and 400+ companies with approximately 200 stocks trading under $5 per share and 80+ private companies. The home page includes an overview of the binary event tracking and personalized VIP services while the secure checkout page includes currently offered discount promo codes at https://mikehavrx.ssl.subhub.com/subscribe

Disclosure: No positions